Dear Investors, Colleagues, and Friends,

This past week, we received great news with another invaluable patent being granted to our portfolio. This one is specific to the United States, patent for SJP-002 - METHODS AND COMPOSITIONS TO INHIBIT SYMPTOMS ASSOCIATED WITH VIRAL UPPER RESPIRATORY TRACT INFECTIONS. This patent provides protection for the work we recently reported in a small case study where we showed we could reduce common cold severity by 75% and duration by 50%. Our advancement in this area could turn the $40B common cold product market on its head given the hot news this week regarding the FDA advisory committee ruling that phenylephrine is ineffective.

This marks a significant step forward in our mission to revolutionize how the world addresses inflammation and how the pharmaceutical industry serves humanity. Our motto, 'Full-Strength Living,' takes on even greater significance in these times of coronavirus, its variants, and common illnesses that challenge humanity's well-being.

From all of us at Sen-Jam Pharmaceutical, we hope you have a fantastic weekend and thanks, as always, for your continued support.

Jim